Compare SHOO & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHOO | IDYA |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.6B |
| IPO Year | 1996 | 2019 |
| Metric | SHOO | IDYA |
|---|---|---|
| Price | $45.06 | $36.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | $42.14 | ★ $52.86 |
| AVG Volume (30 Days) | ★ 979.1K | 661.4K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ 1.38 | N/A |
| Revenue | ★ $2,534,109,000.00 | $218,710,000.00 |
| Revenue This Year | $12.39 | N/A |
| Revenue Next Year | $5.90 | $201.05 |
| P/E Ratio | $32.05 | ★ N/A |
| Revenue Growth | 11.00 | ★ 3024.43 |
| 52 Week Low | $31.33 | $26.05 |
| 52 Week High | $49.70 | $42.68 |
| Indicator | SHOO | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 55.71 | 41.90 |
| Support Level | $41.44 | $34.74 |
| Resistance Level | $46.85 | $38.37 |
| Average True Range (ATR) | 1.37 | 1.28 |
| MACD | 0.37 | -0.28 |
| Stochastic Oscillator | 93.67 | 29.25 |
Steven Madden Ltd and its subsidiaries design, source, and market branded and private label footwear, accessories, and apparel. Its offerings include contemporary styles and core products, known for design creativity, trend-right offerings, high quality, and accessible price points. It operates through four segments: Wholesale Footwear, which generates maximum revenue and sells footwear globally; Wholesale Accessories/Apparel, which sells handbags and apparel through wholesale channels; Direct-to-Consumer, which sells footwear, handbags, apparel, and accessories through stores, outlets, e-commerce, and concessions; and Licensing, which licenses Steve Madden, Betsey Johnson, and Kurt Geiger trademarks, with the Company generating the majority of its revenue from the USA.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.